REG - AstraZeneca PLC - ASTRAZENECA REFINES ITS FINANCIAL REPORTING <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

06/03/2015 07:01

RNS Number : 7428G
AstraZeneca PLC
06 March 2015
AstraZeneca REFINES ITS FINANCIAL REPORTING 
in line with evolving business model
6 March 2015
AstraZeneca today announces an update to the presentation of its Statement of Comprehensive Income, which will see revenue from externalisation becoming more visible to enhance transparency for investors. The change is effective from 1 January 2015 and will be reported as part of the Company's first quarter financial results on 24 April 2015. The impact is presentational and therefore does not impact Reported or Core profit.
As previously outlined, AstraZeneca's business model includes an increasing level of externalisation activity to create value from the strong science that exists in the pipeline. This will benefit patients whilst sharpening further the focus on our main therapy areas - Respiratory, Inflammation & Autoimmunity; Cardiovascular & Metabolic Disease and Oncology. The Company's two biotech centres, the Innovative Medicines Unit and MedImmune, continue to increase R&D productivity. Consequently AstraZeneca will consider opportunities to out-licence technologies and potential new medicines to ensure these reach patients as quickly as possible.
The updated financial reporting structure reflects the Company's entrepreneurial approach and provides a clear picture of a growing additional revenue stream.
Historically, reported revenue reflected only product sales (formerly known as sales revenue), with externalisation revenue forming part of other operating income presented below cost of goods sold (COGS). From 1 January 2015 externalisation revenue, alongside product sales, contribute to total revenue, which is shown above COGS. Externalisation revenue includes development, commercialisation, partnership and out-licence revenue, such as royalties and milestone receipts, together with income from services or repeatable licences.
Income will be recorded as externalisation revenue when the Company has an ongoing interest in the product and/or it is repeatable business and there is no derecognition of an intangible asset. Disposals of assets and businesses, where AstraZeneca does not retain an interest, will continue to be recorded in other operating income.
The Company has updated its revenue accounting policy with effect from 1 January 2015 and the prior-year financial results will be restated accordingly. An illustration of the change to the presentation of prior-period Core financial performance is shown in the appendix. These numbers are unaudited and are indicative of the impact of the change in policy.
2015 Financial Guidance
To reflect the change outlined above, the Company today provides 2015 total revenue guidance. Total revenue is expected to decline by mid single-digit percent at constant exchange rates (CER). This is consistent with previous guidance stating that sales revenue was expected to decline by mid single-digit percent at CER. Core EPS guidance is unchanged and Core EPS is expected to increase by low single-digit percent at CER.
The Company also provides the following non-guidance information related to currency sensitivity: Based on current exchange rates1, total revenue is expected to decline by low double-digit percent. This is consistent with previous expectations stating an anticipated sales revenue decline of low double-digit percent. Core EPS is expected to be broadly in line with 2014. For additional currency sensitivity information, please see below:




Average exchange rates versus USD



Impact of 5% weakening in exchange rate versus USD ($m)2
Currency

Primary relevance

2014

YTD 
Feb 20151

Change
%

Total revenue

Core operating profit
EUR

Product sales

0.75

0.87

(13)

(194)

(119)
JPY

Product sales

105.87

118.55

(11)

(105)

(75)
CNY

Product sales

6.16

6.23

(1)

(113)

(48)
SEK

Costs

6.86

8.22

(16)

(5)

95
GBP

Costs

0.61

0.66

(7)

(34)

104
Other3









(213)

(123)













1Based on average daily spot rates YTD to the end of February 2015.
2Based on 2014 actual group currency exposures.
3Other important currencies include AUD, BRL, CAD, KRW and RUB. 
ENDS -

Appendix
Impact of Revenue Accounting Changes
All numbers shown below are at actual exchange rates in $m unless otherwise stated.

Core Q1 2013
Core Q2 2013
Core Q3 2013
Core Q4 2013
Core FY 2013

Restated
As
Formerly
Presented
Restated
As
Formerly
Presented
Restated
As
Formerly
Presented
Restated
As
Formerly
Presented
Restated
As
Formerly
Presented
Product Sales
6,385
6,385
6,232
6,232
6,250
6,250
6,844
6,844
25,711
25,711
Externalisation Revenue
12
-
47
-
12
-
12
-
83
-
Total Revenue
6,397
6,385
6,279
6,232
6,262
6,250
6,856
6,844
25,794
25,711











Cost of Sales
(1,136)
(1,136)
(1,105)
(1,105)
(1,103)
(1,103)
(1,289)
(1,289)
(4,633)
(4,633)











Gross Profit
5,261
5,249
5,174
5,127
5,159
5,147
5,567
5,555
21,161
21,078











Distribution
(77)
(77)
(76)
(76)
(81)
(81)
(72)
(72)
(306)
(306)
R&D
(963)
(963)
(1,040)
(1,040)
(1,061)
(1,061)
(1,205)
(1,205)
(4,269)
(4,269)
SG&A
(2,055)
(2,055)
(2,173)
(2,173)
(2,154)
(2,154)
(2,483)
(2,483)
(8,865)
(8,865)
Other Income
158
170
171
218
164
176
176
188
669
752











Operating Profit
2,324
2,324
2,056
2,056
2,027
2,027
1,983
1,983
8,390
8,390
All numbers shown below are at actual exchange rates in $m unless otherwise stated.

Core Q1 2014
Core Q2 2014
Core Q3 2014
Core Q4 2014
Core FY 2014

Restated
As
Formerly
Presented
Restated
As
Formerly
Presented
Restated
As
Formerly
Presented
Restated
As
Formerly
Presented
Restated
As
Formerly
Presented
Product Sales
6,416
6,416
6,454
6,454
6,542
6,542
6,683
6,683
26,095
26,095
Externalisation Revenue
49
-
302
-
69
-
41
-
461
-
Total Revenue
6,465
6,416
6,756
6,454
6,611
6,542
6,724
6,683
26,556
26,095











Cost of Sales
(1,193)
(1,193)
(1,156)
(1,156)
(1,180)
(1,180)
(1,359)
(1,359)
(4,888)
(4,888)











Gross Profit
5,272
5,223
5,600
5,298
5,431
5,362
5,365
5,324
21,668
21,207











Distribution
(72)
(72)
(77)
(77)
(87)
(87)
(88)
(88)
(324)
(324)
R&D
(1,098)
(1,098)
(1,208)
(1,208)
(1,275)
(1,275)
(1,360)
(1,360)
(4,941)
(4,941)
SG&A
(2,317)
(2,317)
(2,460)
(2,460)
(2,486)
(2,486)
(2,953)
(2,953)
(10,216)
(10,216)
Other Income
167
216
176
478
187
256
220
261
750
1,211











Operating Profit
1,952
1,952
2,031
2,031
1,770
1,770
1,184
1,184
6,937
6,937

NOTES TO EDITORS
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
CONTACTS
Media Enquiries

Esra Erkal-Paler
+44 20 7604 8030
(UK/Global)
Vanessa Rhodes
+44 20 7604 8037
(UK/Global)
Ayesha Bharmal
+44 20 7604 8034
(UK/Global)
Jacob Lund
+46 8553260 20
(Sweden)
Investor Enquiries

Thomas Kudsk Larsen
+44 20 7604 8199
mob: +44 7818 524185
Karl Hrd
+44 20 7604 8123
mob: +44 7789 654364
Eugenia Litz
+44 20 7604 8233
mob: +44 7884 735627
Craig Marks
+44 20 7604 8591
mob: +44 7881 615764
Christer Gruvris
+44 20 7604 8126
mob: +44 7827 836825
 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCUGUGCWUPAUQQ